Merck joins race to copy Sanofi's diabetes drug Lantus | Business Information & News | Westlaw

Merck joins race to copy Sanofi's diabetes drug Lantus | Business Information & News | Westlaw

View on Westlaw or start a FREE TRIAL today, Merck joins race to copy Sanofi's diabetes drug Lantus, Business Information & News
2/10/14 REUTERS 16:49:13
REUTERS
Copyright © 2014 Thomson Reuters
February 10, 2014
Merck joins race to copy Sanofi's diabetes drug Lantus
Ben Hirschler
(Reuters) - U.S. drugmaker Merck & Co has joined the race to make a cut-price copy of Sanofi's top-selling insulin treatment Lantus, increasing the long-term threat to the French company's $7 billion-a-year product.
Merck, which is working with...
---- Index References ----
Company: SAMSUNG ELECTRONICS CO LTD; ELI LILLY AND CO; MERCK AND CO INC; SANOFI SA
News Subject: (Major Corporations (1MA93); Health & Family (1HE30); General Interest Diabetes (1GE92))
Industry: (Pharmaceuticals (1PH33); Generic Drugs (1GE93); Pharmaceuticals & Biotechnology (1PH13))
Language: EN
Keywords: securities (MCC:OEC); (N2:US); (N2:AMERS); (N2:USA); (MCCL:OVR)
Word Count: 257
End of Document© 2024 Thomson Reuters. No claim to original U.S. Government Works.